Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H23N5O2S.CH4O3S |
| Molecular Weight | 553.653 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CN1C=C(C2=CC=CC=C12)C3=C(C(=O)NC3=O)C4=CN(CCCSC(N)=N)C5=CC=CC=C45
InChI
InChIKey=SAWVGDJBSPLRRB-UHFFFAOYSA-N
InChI=1S/C25H23N5O2S.CH4O3S/c1-29-13-17(15-7-2-4-9-19(15)29)21-22(24(32)28-23(21)31)18-14-30(11-6-12-33-25(26)27)20-10-5-3-8-16(18)20;1-5(2,3)4/h2-5,7-10,13-14H,6,11-12H2,1H3,(H3,26,27)(H,28,31,32);1H3,(H,2,3,4)
DescriptionCurator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21943284 | https://www.ncbi.nlm.nih.gov/pubmed/10998351 | https://www.ncbi.nlm.nih.gov/pubmed/16302800 |
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21943284 | https://www.ncbi.nlm.nih.gov/pubmed/10998351 | https://www.ncbi.nlm.nih.gov/pubmed/16302800 |
RO-31-8220 is a cell-permeable staurosporine analog, that shows potent inhibition of PKC α, PKC βI, PKC βII, PKC γ, and PKC ε. Ro 31-8220 also inhibits MSK1, MAPKAPK1, RSK, GSK3β, and S6K1 with a potency similar to that for PKC. Ro 31-8220 alters cellular protein kinase C localization and potently inhibits the growth of A549 and MCF-7 cells with IC50 of 0.78 μM and 0.897 μM, respectively. RO 31-8220 enhances epinephrine-induced platelet aggregation in catecholamine hypo-responsive platelets by enhancing Akt phosphorylation. Ro 31-8220 significantly decreases apoE secretion from primary human macrophages by inhibiting vesicular transport of apoE to the plasma membrane without significantly affecting apoE mRNA or apoE protein levels.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL262 |
2.8 nM [IC50] | ||
Target ID: CHEMBL2147 |
8.0 nM [Kd] | ||
Target ID: CHEMBL2345 |
10.0 nM [IC50] | ||
Target ID: CHEMBL4501 |
15.0 nM [IC50] | ||
Target ID: CHEMBL4237 |
8.0 nM [IC50] | ||
Target ID: CHEMBL299 |
15.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Studies on the mechanism of fibrate-inhibited expression of plasminogen activator inhibitor-1 in cultured hepatocytes from cynomolgus monkey. | 1997 Jan |
|
| Protein phosphatase-protein kinase interplay modulates alpha 1b-adrenoceptor phosphorylation: effects of okadaic acid. | 2000 Feb |
|
| Regulation of SP-B and SP-C secretion in rat type II cells in primary culture. | 2001 Dec |
|
| Cadmium-induced cell transformation and tumorigenesis are associated with transcriptional activation of c-fos, c-jun, and c-myc proto-oncogenes: role of cellular calcium and reactive oxygen species. | 2001 Jun |
|
| Phosphorylation is involved in the activation of metal-regulatory transcription factor 1 in response to metal ions. | 2001 Nov 9 |
|
| Gene expression profile in BALB/c-3T3 cells transformed with beryllium sulfate. | 2001 Sep |
|
| Acquisition of apoptotic resistance in arsenic-induced malignant transformation: role of the JNK signal transduction pathway. | 2002 Jan |
|
| Regulation of cyclooxygenase-2 expression by phospholipase D in human amnion-derived WISH cells. | 2002 Mar |
|
| Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. | 2003 Mar 15 |
|
| Regulated cell surface pro-EGF ectodomain shedding is a zinc metalloprotease-dependent process. | 2003 Nov 14 |
|
| Roles of protein kinase C, Ca2+, Pyk2, and c-Src in agonist activation of rat lacrimal gland p42/p44 MAPK. | 2006 Aug |
|
| P2Y12 receptor signalling towards PKB proceeds through IGF-I receptor cross-talk and requires activation of Src, Pyk2 and Rap1. | 2006 Aug |
|
| Curcumin inhibits neurotensin-mediated interleukin-8 production and migration of HCT116 human colon cancer cells. | 2006 Sep 15 |
|
| Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycin. | 2007 Feb 1 |
|
| A genomic screen for activators of the antioxidant response element. | 2007 Mar 20 |
|
| Acrolein induces heme oxygenase-1 through PKC-delta and PI3K in human bronchial epithelial cells. | 2008 Apr |
|
| Differential effects of tumor necrosis factor-alpha and interleukin-1beta on cell death in human articular chondrocytes. | 2008 Jun |
|
| Progress in allergy signal research on mast cells: up-regulation of histamine signal-related gene expression in allergy model rats. | 2008 Mar |
|
| Multiple mechanisms are involved in 6-gingerol-induced cell growth arrest and apoptosis in human colorectal cancer cells. | 2008 Mar |
|
| Differential roles of MAPKs and MSK1 signalling pathways in the regulation of c-Jun during phenylephrine-induced cardiac myocyte hypertrophy. | 2009 Feb |
|
| Mechanism of action of the stimulatory effect of apigenin-6-C-(2''-O-alpha-l-rhamnopyranosyl)-beta-L-fucopyranoside on 14C-glucose uptake. | 2009 May 15 |
|
| Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling. | 2009 Nov 15 |
|
| SHAFTS: a hybrid approach for 3D molecular similarity calculation. 2. Prospective case study in the discovery of diverse p90 ribosomal S6 protein kinase 2 inhibitors to suppress cell migration. | 2011 May 26 |
|
| MAPK- and PKC/CREB-dependent induction of interleukin-11 by the environmental contaminant formaldehyde in human bronchial epithelial cells. | 2012 Feb 6 |
Patents
Sample Use Guides
MLP−/− Mice were treated with Ro 31-8220 at dose 6 mg/kg/d, s.c.
Route of Administration:
Other
To compare the effect of PKC inhibition or downregulation on neuritogenesis, at 24 h after plating, the neuroblastoma x •glioma NG108-15 hybrid cells were placed in serum free high-glucose DMEM supplemented with 0.015% dimethyl sulfoxide (DMSO) (control) or 1 mkm Go6983 plus 1 mkm Ro318220 to inhibit PKCs or with 300 nm PMA to downregulate PKCs, and morphological changes were examined after 24 or 48 h.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID00896763
Created by
admin on Sat Dec 16 19:54:07 GMT 2023 , Edited by admin on Sat Dec 16 19:54:07 GMT 2023
|
PRIMARY | |||
|
11628205
Created by
admin on Sat Dec 16 19:54:07 GMT 2023 , Edited by admin on Sat Dec 16 19:54:07 GMT 2023
|
PRIMARY | |||
|
138489-18-6
Created by
admin on Sat Dec 16 19:54:07 GMT 2023 , Edited by admin on Sat Dec 16 19:54:07 GMT 2023
|
PRIMARY | |||
|
3JPC9J3C82
Created by
admin on Sat Dec 16 19:54:07 GMT 2023 , Edited by admin on Sat Dec 16 19:54:07 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
